Cubist Pharmaceuticals 2Q Results: Postgame Scorecard
Cubist Pharmaceuticals (NASDAQ:CBST) swung to a profit in the second quarter.
Earnings and Revenue The company experienced stronger-than-expected EPS and revenues. The company reported EPS of 68 cents a share versus the 49 cents a share estimate and revenues of $230.6 million versus the $226.1 million estimate. The company's reported EPS came in above the high estimate of 10 analysts of a profit of 63 cents.
The company's profit for the quarter was $43.1 million. Revenue climbed 30.4% from $176.8 million in the same period last year.
Company Fundamental Trends The company's revenue has grown during at least each of the past four quarters on a year-over-year basis.
History Against Expectations The company has managed to top estimates the last two quarters. In the first quarter, it beat expectations with net income of 45 cents versus a mean estimate of net income of 41 cents per share.
Estimates provided by Zacks Investment Research and company fundamentals from Xignite Financials.